Preclinical/Co-Clinical Section

临床前/临床联合部分

基本信息

批准号：
10251355
负责人：
Cathleen M Lutz
金额：
$ 15.12万
依托单位：
JACKSON LABORATORY
依托单位国家：
美国
项目类别：
财政年份：
2020
资助国家：
美国
起止时间：
2020-09-01 至 2025-08-31
项目状态：
未结题

来源：
https://reporter.nih.gov/project-details/10251355
关键词：
Address Adoption Animal Model Benchmarking Biology Biomedical Research CLIA certified Client Clinical Clinical Data Clinical Trials Collaborations Collection Communities Data Disease model Drug Kinetics Ensure Faculty Fee-for-Service Plans Felis catus Future Genetic Genomic medicine Goals Grant Health Hospitals Human Human Genetics Individual Industry Industry Collaboration Infrastructure Knowledge Laboratories Lead Medical center Modality Modeling Mouse Strains Mus Patients Pharmacology Phenotype Plug-in Positioning Attribute Preclinical Testing Production Rare Diseases Recommendation Research Research Personnel Resources Role Sampling Series Services Testing The Jackson Laboratory Therapeutic Toxicology Translations Treatment Efficacy Validation Work base clinical application clinical phenotype clinical practice data exchange drug testing experience genomic data human disease in vivo model development operation pre-clinical precision genetics repository somatic cell gene editing tool

项目摘要

PROJECT SUMMARY PRECLINICAL/CO-CLINICAL CORE The Jackson Laboratory (JAX) and The Jackson Laboratory Center for Precision Genetics (JCPG) occupy a unique niche within the global biomedical research community. Although we do not see patients, many of these individuals have benefited from our stewardship of the thousands of different mouse strains that JAX provides for use in human disease research. And it is not just our mice; our faculty researchers, with deep expertise in genetics and mammalian biology, collaborate directly with investigators at hospitals, medical centers and an array of other clinically oriented partners worldwide. Thus, the JCPG will operate using a “hub and spokes” concept where the JCPG forms part of a mammalian disease model “hub” that integrates a variety of JAX resources to establish an array of collaborative “spokes” with a variety of partners to co-produce precise preclinical disease models. The Preclinical/Co-clinical core of the JCPG will work with expert clinical, patient, research and industry collaborators to facilitate optimal creation and application of existing and nominated projects. Together with the JCPG Coordination Core, the Preclinical/Co-clinical Core and the Steering Committee will apply a series of benchmark standards to work toward the eventual goal of translation into clinical practice. Ultimately, we will further extend our impact by providing a more advanced Fee for Service approach to broaden community access to JAX resources. To meet current goals of the JCPG and to refine and expand its future operation, the Preclinical/Co-clinical Core will: 1) Solicit, evaluate and prioritize new preclinical/co-clinical project requests and provide recommendations to the Steering Committee for adoption by the JCPG. 2) Advance new models through the production-like pipelines, with characterization and drug testing so they can more tangibly inform future clinical applications. 3) Continue to develop and expand existing JAX infrastructure to facilitate access to clinical data and samples, supporting data exchange between mouse information and patient data.

项目摘要临床前/临床联合核心杰克逊实验室 (JAX) 和杰克逊实验室精准遗传学中心 (JCPG) 占据全球生物医学研究界的独特利基虽然我们没有看到患者，但其中有许多患者。这些人受益于我们对 JAX 提供的数千种不同小鼠品系的管理不仅是我们的小鼠，我们的研究人员也具有深厚的研究基础。遗传学和哺乳动物生物学方面的专业知识，直接与医院、医疗机构的研究人员合作因此，JCPG 将使用一个“中心”进行运营。和辐条”概念，其中 JCPG 构成哺乳动物疾病模型“中心”的一部分，该模型整合了多种疾病 JAX 资源与各种合作伙伴建立一系列协作“辐条”，共同生产精确的 JCPG 的临床前/临床联合核心将与临床专家、患者、研究和行业合作者，以最佳方式促进现有和提名的创建和应用与 JCPG 协调核心、临床前/临床联合核心和指导一起开展项目。委员会将应用一系列基准标准来努力实现将其转化为最终，我们将通过提供更先进的服务费用来进一步扩大我们的影响。扩大社区对 JAX 资源的访问的方法，以实现 JCPG 的当前目标并完善。并扩大其未来的运营，临床前/临床联合核心将： 1) 征求、评估和优先考虑新的临床前/临床联合项目请求并向指导委员会提供建议以供通过 2) 通过类似生产的管道推进新模型，包括表征和药物。测试，以便他们能够更切实地为未来的临床应用提供信息 3) 继续开发和扩展。现有的 JAX 基础设施可促进临床数据和样本的访问，支持之间的数据交换小鼠信息和患者数据。